MétaCan
Menu
Back to cohort
Record W4405374727 · doi:10.1016/j.iotech.2024.100823

80P Tumor markers evolution in pts treated with TCE and association with radiologic response

2024· article· en· W4405374727 on OpenAlexfundno aff
Constance d’Abrigeon, Kaïssa Ouali, Noé Herbel, Stéphane Champiat, Antoine Hollebecque, C. Smolenschi, Madona Sakkal, Ratislav Bahleda, Anas Gazzah, Anna Patrikidou, Jean‐Marie Michot, Thomas Hueso, S. Ammari, Y. Loriot, C. Massard, A. Bernard-Tessier, M. Texier, C. Baldini

Bibliographic record

VenueImmuno-Oncology Technology · 2024
Typearticle
Languageen
FieldMedicine
TopicMedical Imaging and Pathology Studies
Canadian institutionsnot available
FundersCilagLoxo OncologyChugai PharmaceuticalNovartis PharmaGenentechPharmaMarBasilea PharmaceuticaAstellas PharmaEisaiEisai CanadaBeiGeneRelay TherapeuticsSeagenAgios PharmaceuticalsLes Laboratories Pierre FabrePfizerIncyteBoston PharmaceuticalsMerck KGaATaiho PharmaceuticalDaiichi Sankyo EuropeServierFoghorn TherapeuticsGilead SciencesBayer HealthCareExelixisSanofiGlaxoSmithKlineAmgenCelgeneInstitut National Du CancerAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsAssociation (psychology)Internal medicineMedicineOncologyPsychologyPsychotherapist

Abstract

fetched live from OpenAlex

Background: This study aims to identify a new prognostic index for patients with biliary tract cancer (BTC) treated with cisplatin, gemcitabine and durvalumab (CGD) in first-line setting. Methods:The study population consisted of 319 patients with BTC from 11 Eastern and Western Countries.Using multivariate analysis, we previously developed a prognostic model called the CGD index by combining the 5 baseline positive variables and assigning a weight from 1 to 5 as follows: 1 for metastatic disease, 2 for CEA increased levels, 3 for albumin decreased levels, 4 for GGT increased levels, 5 for NLR 3. Patients were stratified into three risk-groups as follows: low risk-group (RG) (score from 0 to 5), intermediate RG (score from 6 to 10), and high RG (score from 11 to 15).Results: Median progression-free survival was 10.5 months (95% CI: 8.4-11.9months) in low RG (27.3%), 8.7 months (95% CI: 7.1-9.9months) in intermediate RG (38.9%), and 5.5 months (95% CI: 4.4-7.4months) in high RG (33.8%; low risk HR: 0.44, intermediate risk HR: 0.63, high risk HR: 1, p<0.01].Median overall survival was 17.9 months (95% CI: 13.5-17.9months) in low RG,15.6 months (95% CI: 10.2-18.4months) in intermediate RG, and 8.0 months (95% CI: 7.4-12.5 months) in high RG (low risk HR: 0.32, intermediate risk HR: 0.52, high risk HR: 1, p<0.01).There was no difference in objective response rate (low risk: 28.7%, intermediate risk: 36.3%, and high risk: 29.6%; p¼0.26), while disease control rate was significantly different in the three RGs (low risk: 78.2%, intermediate risk: 72.6%, and high risk: 61.1%; p<0.01) as well as the rate of patients receiving a second-line therapy (low risk: 21.8%, intermediate risk: 23.4%, and high risk: 17.6%; p¼0.02).The safety profile was similar in the three RGs, except for nausea (low risk: 36.8%,intermediate risk: 42.7%, high risk: 26.8%; p¼0.04), leukopenia (low risk: 28.7%, intermediate risk: 33.1%, high risk: 16.7%; p¼0.01), and neutropenia (low risk: 55

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.274
Teacher spread0.267 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractno

Explore more

Same venueImmuno-Oncology TechnologySame topicMedical Imaging and Pathology StudiesFrench-language works237,207